Clinical Trials Logo

Classic Hodgkin Lymphoma clinical trials

View clinical trials related to Classic Hodgkin Lymphoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06465446 Not yet recruiting - Clinical trials for Classic Hodgkin Lymphoma

A Study of IMM01 in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma

Start date: June 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of IMM01 plus Tiselizumab. The primary study hypotheses are that IMM01 plus Tiselizuma is superior to physician's choice chemotherapy with respect to progression-free survival (PFS) and overall survival (OS).

NCT ID: NCT06377540 Not yet recruiting - Clinical trials for Classic Hodgkin Lymphoma

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Start date: August 1, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant.

NCT ID: NCT05949931 Not yet recruiting - Clinical trials for Classic Hodgkin Lymphoma

Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

Start date: August 2023
Phase: Phase 2
Study type: Interventional

This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.